Bionik Laboratories Corp.

Equities

BNKL

US09074A2087

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 08:10:00 2023-11-29 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2023	Bionik Laboratories Corp. Announces Executive Changes	CI
2023	Bionik Laboratories Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Bionik Laboratories Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022

November 09, 2022 at 07:30 am EST

Bionik Laboratories Corp. reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was USD 0.486205 million compared to USD 0.227905 million a year ago. Net loss was USD 1.13 million compared to USD 1.27 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 0.16 compared to USD 0.22 a year ago.
For the six months, sales was USD 0.729034 million compared to USD 0.899188 million a year ago. Net loss was USD 2.51 million compared to USD 1.72 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.3 a year ago. Diluted loss per share from continuing operations was USD 0.37 compared to USD 0.3 a year ago.

Latest news about Bionik Laboratories Corp.

Bionik Laboratories Corp. Announces Executive Changes	23-06-27	CI
Bionik Laboratories Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-21	CI
Bionik Laboratories Corp. Auditor Raises 'Going Concern' Doubt	23-06-20	CI
Bionik Laboratories Corp. Expands Its Partnership With Lifepoint Health With the Installation of InMotion® Robotic Devices at Four New Locations	23-06-15	CI
Bionik Laboratories Corp. announced that it expects to receive $2 million in funding	23-06-12	CI
Bionik Laboratories Corp. announced that it has received $0.25 million in funding	23-04-19	CI
Bionik Laboratories Corp. announced that it has received $0.5 million in funding	23-02-15	CI
Bionik Laboratories Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q3 Revenue $575.1M	23-02-08	MT
Bionik Laboratories Corp. announced that it has received $0.4 million in funding from Gd Holding	22-11-13	CI
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q2 Revenue $486.2M	22-11-09	MT
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q2 Loss $-0.15	22-11-09	MT
Bionik Laboratories Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-09	CI
Bionik Laboratories Corp. Appoints Richard Russo as Chief Executive Officer	22-10-13	CI
Bionik Laboratories Corp. Appoints Richard Russo as President	22-10-13	CI
Bionik Laboratories Corp. Appoints Dan Gonsalves as Chief Financial Officer	22-10-13	CI
Bionik Laboratories Corp. acquired Florida Rehabilitation Center.	22-09-07	CI
Bionik Laboratories Corp. announced that it expects to receive $0.25 million in funding from Gd Holding	22-09-01	CI
Bionik Laboratories Corp. Announces Resignation of Gerald Malone as Independent Director as Well as Chairman of Its Compensation Committee and Member of Its Audit Committee	22-08-31	CI
Bionik Laboratories Corp. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-10	CI
Earnings Flash (BNKL) BIONIK LABORATORIES Reports Q1 Revenue $242,829	22-08-10	MT
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q1 Loss $-0.19	22-08-10	MT
Bionik Laboratories Corp. Terminates Employment of Loren was as Chief Commercial Officer	22-07-06	CI
Bionik Laboratories Corp. Announces the Sale & Installation of a New InMotion® ARM/HAND Robotic Device to Tampa General Hospital for its Rehabilitation Center	22-06-23	CI
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q4 Revenue $191,262	22-06-09	MT

Chart Bionik Laboratories Corp.

Duration

Period

More charts

Company Profile

Bionik Laboratories Corp. is a robotics company, which provides neurological functional recovery solutions to stroke survivors and others with neurological and mobility challenges. It uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and deliver recovery for patients with neurological or mobility impairments. It has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. Its InMotion ARM, and InMotion ARM/HAND products are robotic therapies for the upper limbs. In addition to these fully developed, clinical rehabilitation solutions, it is also developing InMotion Home, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home. Its other products are InMotion Robots and InMotion CONNECT.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIONIK LABORATORIES CORP.	-.--%	12
ABBOTT LABORATORIES	-3.79%	184B
MEDTRONIC PLC	-0.84%	108B
BECTON, DICKINSON AND COMPANY	-3.75%	67.82B
DEXCOM, INC.	+3.45%	51.05B
CENCORA, INC.	+9.04%	44.67B
HOYA CORPORATION	+3.40%	41.78B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.78B
WEST PHARMACEUTICAL SERVICES, INC.	+3.66%	26.59B
TERUMO CORPORATION	+15.23%	25.86B

Other Medical Equipment, Supplies & Distribution